TAG:
Esoteric testing
Esoteric testing allows the analysis of rare substances or molecules that are not performed in a routine clinical lab. Many large commercial lab companies outsource complex tests to reference and esoteric testing labs. However, as technology continues to expand laboratory testing, tests that are considered esoteric today may become routine in just a few years. This is often the result of work performed by dedicated research and development scientists.
These tests are ordered when a physician requires additional detailed information, outside routine lab testing, to complete a diagnosis, establish a prognosis or choose and monitor a therapeutic regimen. Esoteric testing generally requires sophisticated instruments and materials as well as specialized personnel to perform and analyze results. The tests are typically outsourced to independent, specialized clinical reference laboratories because it is not cost effective for hospitals and physician office laboratories to perform the tests in-house.
These tests are ordered less frequently than routine tests and are generally priced higher than the routine tests. Esoteric testing is typically related to the medical fields such as endocrinology, genetics, immunology, microbiology, molecular diagnostics, oncology, serology and toxicology. Molecular diagnostics is the fastest growing segment of esoteric clinical testing.
The American Chemical Society publishes the Directory of Rare Analyses (DORA) which catalogues rarely ordered clinical tests and provides details on the labs performing them.
The challenges for labs performing such tests include not only finding qualified medical technologists, but also paying them the higher salaries they command because of the scarcity of their skill sets. In addition, materials used in these tests can also be costly, particularly because they are not usually purchased in large enough quantities to qualify for economies of scale.
Labs that perform these tests have capabilities including:
• Allergy
• Complex anatomic pathology with board-certified pathologist
• Bone markers
• Genetic analysis
• HLA testing
• Functional assays of the immune system
• Toxicology
In the U.S., labs that perform these tests range from ARUP Laboratories, Mayo Medical Laboratories, Quest Diagnostics Incorporated, and Laboratory Corporation of America to a growing number of specialty esoteric testing laboratories that offer proprietary esoteric assays. Examples of such specialty testing lab companies include Myriad Genetics, Genomic Health, and Foundation Medicine.
Are Two Blood Brothers Using Economic Clout?
By Robert Michel | From the Volume X No. 10 – July 28, 2003 Issue
CEO SUMMARY: Quest Diagnostics Incorporated and Laboratory Corporation of America now dominate the national marketplace for testing referred by physicians’ offices. Release of their second quarter earnings reports provides the first look at their performance following the acquisitions i…
LabCorp’s MacMahon Provides Insights About Lab Marketplace
By Robert Michel | From the Volume X No. 5 – April 14, 2003 Issue
CEO SUMMARY: Pathologists will be particularly interested in what Thomas MacMahon has to say about the evolution of laboratory medicine. As Chairman, President, and CEO of Laboratory Corporation of America Holdings, he has continuous access to some of the best strategic analysis about the…
Bio-Reference Labs, Quest Diagnostics, TriPath Imaging, Specialty Labs, SARS
By Robert Michel | From the Volume X No. 4 – March 24, 2003 Issue
BIO-REFERENCE LABS POSTS 20% INCREASE IN ANNUAL NET REVENUE LAST YEAR’S FRENZY of laboratory acquisitions left Bio-Reference Laboratories, Inc. of Elmwood Park, New Jersey as the nation’s third-largest public laboratory company focused primarily on physicians’ office t…
Lab Director Takes a Stand On Patented Genetic Testing
By Robert Michel | From the Volume X No. 3 – March 3, 2003 Issue
THIS LETTER APPEARED in the mailbag after our special intelligence briefing on how genetics will transform healthcare and before our look at how high-priced specialty esoteric testing is causing budget headaches for regional labs. (See TDRs, December 30, 2002 and …
New Trends in 2003 Affect Clinical Lab Services
By Robert Michel | From the Volume X No. 1 – January 20, 2003 Issue
CEO SUMMARY: Here’s our current list of macro trends that affect clinical laboratories, updated from the last list in January 2000. One bold prediction is that Medicare, as we know it, is on the verge of a major meltdown. Employers and consumers are also new forces to be reckoned with b…
New Market Channel For Esoteric Testing
By Robert Michel | From the Volume X No. 1 – January 20, 2003 Issue
CEO SUMMARY: It’s a new marketing model for specialty esoteric tests that presents both clinical and financial challenges to hospital and health system laboratories. Niche labs offering esoteric tests are sending sales reps directly to physicians and bypassing pathologists and lab direc…
Another Lab Acquisition: LabCorp To Buy DIANON
By Robert Michel | From the Volume IX No. 16 – November 18, 2002 Issue
CEO SUMMARY: Laboratory Corporation of America Holdings will pay almost $598 million to buy DIANON Systems, Inc. of Stratford, Connecticut. With this move, anatomic pathology becomes a high profile growth target for LabCorp. During the past eight years, DIANON Systems has built a national…
Hospitals in Michigan Build Unique Shared Lab
By Robert Michel | From the Volume IX No. 15 – October 28, 2002 Issue
CEO SUMMARY: This operational model for a collaborative regional laboratory organization makes “profit” irrelevant. Serving 30 hospitals in four Midwestern states, Michigan Co-Tenancy Laboratories is consistently expanding lab testing services, lowering costs, and emphasizing the labo…
ARUP & Mayo Respond To New Market Cycle
By Robert Michel | From the Volume IX No. 14 – October 7, 2002 Issue
CEO SUMMARY: Since the beginning of 2002, several important events changed the competitive status quo among the nation’s leading providers of hospital send-out testing. As part of its ongoing assessment of this market segment, THE DARK REPORT provides strategic management insights from …
Esoterix Ready to Launch National Marketing Blitz
By Robert Michel | From the Volume IX No. 13 – September 16, 2002 Issue
CEO SUMMARY: It was 1995 when several specialty testing lab companies were acquired by a new company called Esoterix. Immediately the lab industry viewed Esoterix as a “put-together” lab company. However, since 2000, executives at Esoterix have invested $50 million to integrate operat…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized